Plain-English translation of NCT04146298 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer. Researchers take your own immune cells, genetically engineer them in the laboratory to recognize and attack pancreatic cancer cells with a specific genetic mutation, and then infuse them back into your body. The goal is to see whether this treatment is safe and whether it can help shrink tumors.
Most pancreatic cancers have a mutation in a gene called KRAS that helps cancer cells grow, and current treatments don't always work well against it. This trial exists because researchers have discovered that immune cells can be trained to recognize and attack cancer cells with this specific mutation, and early results in other cancer types suggest this approach may work.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive chemotherapy to prepare your body, then your immune cells will be collected and sent to the laboratory to be engineered. After the cells are ready, you will receive an infusion of the treated cells back into your body. You may also receive additional medications to help support the immune cells. You will have regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for any side effects. If the cancer starts to grow again, you may be offered additional cell infusions.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China